Skip to main content

Advertisement

Log in

A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Immunosuppressants lead to an increased risk of infection, but few prospective studies have assessed the incidence of opportunistic infections in inflammatory bowel disease (IBD) patients, a high proportion of whom are treated with immunosuppressants. The aim of this study was to assess the age distribution of Japanese IBD patients with opportunistic infections and the risk factors associated with these infections.

Methods

A multicenter, prospective study of 570 IBD patients was conducted. The patients were followed for up to 12 months to identify any new infections. The incidence of opportunistic infections and the age distribution of patients with these infections were analyzed. We carried out a case–control study in which 2 non-infected IBD patients were selected as controls for each case (infected IBD patient); the effect of medications on the infection rate was also examined.

Results

Fifty-two (9.1 %) of 570 IBD patients developed opportunistic infections. Herpes simplex virus and herpes zoster virus infections were observed in 29 and 16 patients, respectively. No cases of active tuberculosis were observed. The incidence of opportunistic infections in patients aged 50 years or over was significantly higher than that in the other age groups (p = 0.01). The use of steroids (p = 0.02), thiopurine (p < 0.01), and immunosuppressant combination therapy (p < 0.01) was associated with an increased rate of opportunistic infections. However, the use of infliximab was not associated with an increased rate of opportunistic infections (p = 0.62). Multivariate analysis indicated that the use of thiopurine was an independent risk factor for opportunistic infections (p < 0.01).

Conclusions

Age ≥50 years and the use of immunosuppressants are risk factors for opportunistic infections in patients with IBD. In our cohort, tuberculosis was not seen as a complication of immunosuppressant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549–58.

    Article  PubMed  CAS  Google Scholar 

  2. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2009;3:47–91.

    Article  CAS  Google Scholar 

  3. Kollas G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 2002;13:315–21.

    Article  Google Scholar 

  4. Duchet-Niedziolka P, Coutsinos Z, Hanslik T. Anti-TNFα therapy and vaccine of adults. Joint Bone Spine. 2007;74:563–5.

    Article  PubMed  CAS  Google Scholar 

  5. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.

    Article  PubMed  Google Scholar 

  6. Naganuma M, Fujii T, Kunisaki R, Yoshimura N, Takazoe M, Takeuchi Y, et al. Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. J Crohns Colitis. 2012 (epub ahead of print).

  7. Naganuma M, Kunisaki R, Yoshimura N, Nagahori M, Yamamoto H, Kimura H, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohn’s Colitis. 2011;5:317–23.

    Article  Google Scholar 

  8. Komiyama T, Yajima T, Kubota R, Iwao Y, Sakuraba A, Funakoshi S, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohn’s Colitis. 2008;2:315–21.

    Article  Google Scholar 

  9. Hammer SM. Clinical practice: management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702–10.

    Article  PubMed  Google Scholar 

  10. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–37.

    Article  PubMed  Google Scholar 

  11. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.

    Article  PubMed  CAS  Google Scholar 

  12. D’Haens G, Colombel JF, Hommes DW. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology. 2008;134:A140.

    Google Scholar 

  13. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–33.

    Article  PubMed  Google Scholar 

  14. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64:2763–92.

    Article  PubMed  CAS  Google Scholar 

  15. Fillet AM. Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients. Drugs Aging. 2002;19:343–54.

    Article  PubMed  CAS  Google Scholar 

  16. Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2012 (epub ahead of print).

  17. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.

    Article  PubMed  CAS  Google Scholar 

  18. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837–46.

    Article  PubMed  CAS  Google Scholar 

  19. Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90–6.

    Article  PubMed  CAS  Google Scholar 

  20. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumour necrosis factor α therapies in elderly patients with rheumatoid arthritis. Arthr Rheum. 2007;57:679–85.

    Article  Google Scholar 

  21. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthr Rheum. 2007;56:1754–64.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to express their thanks to Nature Publishing Group Language Editing for editing the manuscript to improve the English language usage.

Conflict of interest

For this project, Mamoru Watanabe received a research grant from Health and Labour Sciences Research Grants for Research On Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Makoto Naganuma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naganuma, M., Kunisaki, R., Yoshimura, N. et al. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol 48, 595–600 (2013). https://doi.org/10.1007/s00535-012-0686-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-012-0686-9

Keywords

Navigation